Sofinnova Venture Partners X L.P. 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-20 7:09 pm Purchase |
2023-06-21 | 13D | Aerovate Therapeutics, Inc. AVTE |
Sofinnova Venture Partners X L.P. | 3,807,315 13.800% |
23,683 (+0.63%) |
Filing |
| 2023-02-03 7:24 pm Purchase |
2022-11-14 | 13D | Aerovate Therapeutics, Inc. AVTE |
Sofinnova Venture Partners X L.P. | 3,783,632 15.400% |
23,558 (+0.63%) |
Filing |
| 2021-07-13 1:49 pm Purchase |
2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE |
Sofinnova Venture Partners X L.P. | 3,760,074 16.300% |
3,760,074 (New Position) |
Filing |